Berlin’s Ethnological Museum: The California Indian Collection

The Ethnologisches Museum: Staatliche Museen zu Berlin (formerly the Museum für Völkerkunde, and referred to here as the Berlin Ethnological Museum) contains over 1,000 artifacts fashioned by California Indians, collected between 1837 and 1914. The collection is rich and varied; it represents one of the earliest ethnographic collections from Native California and includes ethnological treasures of great aesthetic quality and rarity. The collection is an invaluable source of scientific information and cultural renewal. The objects are highly regarded by living descendants of the Native Californians who long ago sold, traded, and exchanged these artifacts with collectors. They are heirlooms reflecting tribal history and culture, and are worthy of remembrance and study. In this paper we offer first-hand observations on a small sample (n =10) of the Berlin Ethnological Museum’s California Indian collection, with a particular emphasis on baskets. We describe and discuss these objects in detail in order to bring to life the people and cultures that brilliantly produced such exquisite, artistic objects and ethnographic treasures. We also attempt to identify their historical context and the circumstances motivating their collection, so as to better understand how they came to be curated in Berlin. Finally, we provide a brief overview of the history and development of the Berlin Ethnological Museum’s California Indian collection, because the intriguing interconnections and influential coincidences associated with it provide insights into the history and nature of the early development of California Indian studies and particularly illuminate the evolution of the science of anthropology as an academic discipline in America

BodilisantA Novel Fluorescent, Highly Affine Histamine H₃ Receptor Ligand

A piperidine-based lead structure for the human histamine H₃ receptor (hH₃R) was coupled with the BODIPY fluorophore and resulted in a strong green fluorescent (quantum yield, 0.92) hH₃R ligand with affinity in the nanomolar concentration range (<i>K</i>_i hH₃R = 6.51 ± 3.31 nM), named Bodilisant. Screening for affinities at histamine and dopamine receptor subtypes showed high hH₃R preference. Bodilisant was used for visualization of hH₃R in hH₃R overexpressing HEK-293 cells with fluorescence confocal laser scanning microscopy. In addition, in native human brain tissues, Bodilisant showed clear and displaceable images of labeled hH₃R

Outcomes in Patients with Vasodilatory Shock and Renal Replacement Therapy Treated with Intravenous Angiotensin II.

OBJECTIVE: Acute kidney injury requiring renal replacement therapy in severe vasodilatory shock is associated with an unfavorable prognosis. Angiotensin II treatment may help these patients by potentially restoring renal function without decreasing intrarenal oxygenation. We analyzed the impact of angiotensin II on the outcomes of acute kidney injury requiring renal replacement therapy. DESIGN: Post hoc analysis of the Angiotensin II for the Treatment of High-Output Shock 3 trial. SETTING: ICUs. PATIENTS: Patients with acute kidney injury treated with renal replacement therapy at initiation of angiotensin II or placebo (n = 45 and n = 60, respectively). INTERVENTIONS: IV angiotensin II or placebo. MEASUREMENTS AND MAIN RESULTS: Primary end point: survival through day 28; secondary outcomes included renal recovery through day 7 and increase in mean arterial pressure from baseline of ≥ 10 mm Hg or increase to ≥ 75 mm Hg at hour 3. Survival rates through day 28 were 53% (95% CI, 38%-67%) and 30% (95% CI, 19%-41%) in patients treated with angiotensin II and placebo (p = 0.012), respectively. By day 7, 38% (95% CI, 25%-54%) of angiotensin II patients discontinued RRT versus 15% (95% CI, 8%-27%) placebo (p = 0.007). Mean arterial pressure response was achieved in 53% (95% CI, 38%-68%) and 22% (95% CI, 12%-34%) of patients treated with angiotensin II and placebo (p = 0.001), respectively. CONCLUSIONS: In patients with acute kidney injury requiring renal replacement therapy at study drug initiation, 28-day survival and mean arterial pressure response were higher, and rate of renal replacement therapy liberation was greater in the angiotensin II group versus the placebo group. These findings suggest that patients with vasodilatory shock and acute kidney injury requiring renal replacement therapy may preferentially benefit from angiotensin II